SalvorHardin wrote: TheMotorcycleBoy wrote:
I wondered if there were any other things that attracted you to Moderna, other than their recent success in the Covid mRNA vaccine
I don't know much about them and was wondering how different this company is to the likes of AstraZeneca, Pfizer, El Lily etc. who seem themselves to be described as "Pharmaceutical", where as Moderna are as "Biotechnical".
For me, a huge factor with Moderna is that mRNA technology is at the heart of everything that the company does.
All of its treatments and those still in the pipeline use mRNA. That isn't the case for the Pharmaceutical companies.
So if mRNA does live up to its promise, Moderna should have a very strong position. I just haven't a clue as to how big that could be.
I plan to look at MRNA in more detail sometime soon. I took a quick look at their wiki page
and noted that their initial interest, seemed to be in stem cell research and cancer treatments. I put those two together and arrived at articles such as Stem cell transplants in cancer treatment
I note that it was in about 2018 that the vaccine research research portfolio was increased, and at the tail end of the same year, they IPOd:In 2018, the company rebranded as "Moderna Inc." with the ticker symbol MRNA, and further increased its portfolio of vaccine development. In December 2018, Moderna became the largest biotech initial public offering in history, raising $621 million (27 million shares at $23 per share) on NASDAQ, and implying an overall valuation of $7.5 billion for the entire company. The year-end 2019 SEC filings showed that Moderna had accumulated losses of $1.5 billion since inception, with a loss of $514 million in 2019 alone, and had raised $3.2 billion in equity since 2010. As of December 2020, Moderna was valued at $60 billion.
In March 2020, in a White House meeting between the Trump administration and pharmaceutical executives, Bancel told the president that Moderna could have a COVID-19 vaccine ready in a few months. The next day, the FDA approved clinical trials for the Moderna vaccine candidate, with Moderna later receiving investment of $483 million from Operation Warp Speed. Moderna board member, Moncef Slaoui, was appointed head scientist for the Operation Warp Speed project.
Given that so far they are still making a loss, I wonder, how do businesses such as these get monetised? That is, turn the loss into profit, do organisations like our NHS, and in America private health care companies strike up contracts with them?
We are also aware of their partnership with AZN, so I'm curious as to whether that relationship will facilitate more of MRNA's mRNA products appearing in chemist shops.